Core Viewpoint - A securities class action lawsuit has been filed against ICON Public Limited Company for allegedly making materially false and misleading statements regarding its business operations and financial health during the Class Period from July 27, 2023, to October 23, 2024 [1]. Group 1: Allegations Against ICON - The lawsuit claims that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations impacting its client base [2]. - It is alleged that ICON's hybrid model offerings were inadequate to protect the company from a significant market downturn [2]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools rather than indicative of actual client demand [2]. - Customers of ICON are said to have canceled contracts, limited engagements, delayed clinical trial work, and failed to enter into new contracts at historical rates [2]. - The two largest customers of ICON were diversifying their providers away from the company [2]. - As a result of these issues, ICON's reported net new business awards and book-to-bill metrics allegedly misrepresented actual client demand for its services [2]. - Positive statements made by ICON regarding its business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Lead Plaintiff Process - ICON investors have until April 11, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]. - The firm aims to protect investors and others from fraud and negligence by businesses [4].

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR).Shareholders who purchased shares of ICLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/icon-public-limited-company-loss-submission-form/?id=134601&from=4CLASS PERI ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ICON Public Limited Company ("ICON " or the "Company") (NASDAQ: ICLR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ICON  investors who were adversely affected by alleged securities fraud between July 27, 2023 and October 23, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/icon-public-limited-company ...

Core Viewpoint - A securities class action lawsuit has been filed against ICON Public Limited Company for allegedly making materially false and misleading statements regarding its business operations and financial health during the Class Period from July 27, 2023, to October 23, 2024 [1]. Group 1: Allegations Against ICON - The lawsuit claims that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations impacting its client base [2]. - It is alleged that ICON's hybrid model offerings were inadequate to protect the company from a significant market downturn [2]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools rather than indicative of actual client demand [2]. - Customers of ICON are said to have canceled contracts, limited engagements, delayed clinical trial work, and failed to enter into new contracts at historical rates [2]. - The two largest customers of ICON were diversifying their providers away from the company [2]. - As a result of these issues, ICON's reported net new business awards and book-to-bill metrics allegedly misrepresented actual client demand [2]. - Positive statements made by ICON regarding its business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Lead Plaintiff Process - ICON investors have until April 11, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]. - The firm aims to protect investors and others from fraud and negligence by businesses [4].

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR). Shareholders who purchased shares of ICLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/icon-public-limited-company-loss-submission-form/?id=134072&from=3 CL ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR).Shareholders who purchased shares of ICLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/icon-public-limited-company-loss-submission-form/?id=134051&from=4CLASS PERIO ...

BERWYN, Pa.  and DUBLIN, March 4, 2025 /PRNewswire/ -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organization, today announce a partnership to utilize the participant management and payments platform, Mural Link. ICON will utilize Mural Link's innovative functionality related to clinical trial participant payments, tax management, travel and concierge support, site-participant commun ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ICON plc (NASDAQ: ICLR) and certain of its senior executives for potential violations of the federal securities laws. If you invested in ICON, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/icon-plc. Investors have until April 11, 2025, to ask the Court to be appointed to lead the case. The complaint a ...

Core Viewpoint - ICON PLC is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misrepresented its business performance and client demand during a significant downturn in the market [1][2]. Company Summary - The class action lawsuit, titled Shing v. ICON plc, involves purchasers of ICON ordinary shares from July 27, 2023, to October 23, 2024, who are seeking to be appointed as lead plaintiffs [1]. - Allegations against ICON include that the company suffered a material loss of business due to customer cost reduction measures and funding limitations impacting its client base [2]. - It is claimed that ICON's Functional Service Provision (FSP) and hybrid model offerings were inadequate to mitigate the effects of a market downturn [2]. - The lawsuit asserts that requests for proposals from biotechnology customers were primarily used for price discovery rather than indicating actual client demand [2]. - Significant issues reported include canceled contracts, reduced engagements, and delays in clinical trial work, leading to a decline in new contracts at historical rates [2]. - The two largest customers of ICON were reportedly diversifying their CRO providers away from ICON, further impacting the company's business [2]. Financial Performance - On October 23, 2024, ICON reported third fiscal quarter revenues of $2.03 billion, missing consensus estimates of $2.13 billion by over $100 million [3]. - The company's net new business wins declined sequentially to $2.3 billion from $2.6 billion in the previous quarter, with a book-to-bill ratio falling to 1.15 from 1.22 [3]. - CEO Stephen Cutler indicated that ongoing cost containment measures from large pharmaceutical customers would continue to negatively affect ICON's financial performance [3]. - Following the financial results announcement, ICON's share price dropped by more than 20% over two trading sessions [3].

NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ICON Public Limited Company ("Icon" or the "Company") (NASDAQ :ICLR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Icon and certain of its office ...